{"relation": [["Property", "Human Intestinal Absorption", "Blood Brain Barrier", "Caco-2 permeable", "P-glycoprotein substrate", "P-glycoprotein inhibitor I", "P-glycoprotein inhibitor II", "Renal organic cation transporter", "CYP450 2C9 substrate", "CYP450 2D6 substrate", "CYP450 3A4 substrate", "CYP450 1A2 substrate", "CYP450 2C9 substrate", "CYP450 2D6 substrate", "CYP450 2C19 substrate", "CYP450 3A4 substrate", "CYP450 inhibitory promiscuity", "Ames test", "Carcinogenicity", "Biodegradation", "Rat acute toxicity", "hERG inhibition (predictor I)", "hERG inhibition (predictor II)"], ["Value", "+", "-", "-", "Non-substrate", "Non-inhibitor", "Non-inhibitor", "Non-inhibitor", "Non-substrate", "Non-substrate", "Non-substrate", "Non-inhibitor", "Non-inhibitor", "Non-inhibitor", "Non-inhibitor", "Non-inhibitor", "Low CYP Inhibitory Promiscuity", "Non AMES toxic", "Non-carcinogens", "Ready biodegradable", "1.2108 LD50, mol/kg", "Weak inhibitor", "Non-inhibitor"], ["Probability", "0.939", "0.6054", "0.9009", "0.7827", "0.9851", "0.9902", "0.9634", "0.8233", "0.8832", "0.8021", "0.8694", "0.9362", "0.9529", "0.9119", "0.8683", "0.9806", "0.9538", "0.6811", "0.844", "Not applicable", "0.9902", "0.9826"]], "pageTitle": "DrugBank: L-Threonine (DB00156)", "title": "", "url": "http://www.drugbank.ca/drugs/DB00156", "hasHeader": true, "headerPosition": "FIRST_ROW", "tableType": "RELATION", "tableNum": 3, "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988650.6/warc/CC-MAIN-20150728002308-00113-ip-10-236-191-2.ec2.internal.warc.gz", "recordEndOffset": 406394169, "recordOffset": 406378535, "tableOrientation": "HORIZONTAL", "TableContextTimeStampAfterTable": "{19528=Masato Terasawa, Yukie Satoo, Hideaki Yukawa, \u201cMethod for production of l-threonine.\u201d U.S. Patent US5019503, issued June, 1967.}", "textBeforeTable": "Predicted ADMET features ADMET Not Available SNP Mediated Adverse Drug Reactions Not Available SNP Mediated Effects SMP00728 Drug action Lincomycin Action Pathway SMP00295 Drug action Lymecycline Action Pathway SMP00258 Drug action Spectinomycin Action Pathway SMP00253 Drug action Amikacin Action Pathway SMP00251 Drug action Roxithromycin Action Pathway SMP00727 Drug action Methacycline Action Pathway SMP00714 Drug action Paromomycin Action Pathway SMP00712 Drug action Tigecycline Action Pathway SMP00294 Drug action Tetracycline Action Pathway SMP00257 Drug action Netilmicin Action Pathway SMP00252 Drug action Telithromycin Action Pathway SMP00250 Drug action Erythromycin Action Pathway SMP00731 Drug action Josamycin Action Pathway SMP00726 Drug action Rolitetracycline Action Pathway SMP00713 Drug action Arbekacin Action Pathway SMP00711 Drug action Tobramycin Action Pathway SMP00293 Drug action Oxytetracycline Action Pathway SMP00291 Drug action Doxycycline Action Pathway", "textAfterTable": "Pharmacoeconomics Manufacturers Not Available Packagers Hospira Inc. Novis PR Inc. Spectrum Pharmaceuticals V Sab Medical Labs Inc. Dosage forms Not Available Prices Unit description Cost Unit L-threonine crystal 4.57USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only. Patents Not Available Properties State Solid Experimental Properties Property Value Source melting point 256 dec \u00b0C PhysProp water solubility 9.7E+004 mg/L (at 25 \u00b0C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP -2.94 HANSCH,C ET AL. (1995) logS -0.09 ADME Research, USCD pKa 5.60 Not Available Predicted Properties Property Value Source Water Solubility 477.0 mg/mL ALOGPS logP -3 ALOGPS logP -3.5 ChemAxon logS 0.6 ALOGPS pKa (Strongest Acidic) 2.21 ChemAxon pKa (Strongest Basic) 9 ChemAxon Physiological Charge 0 ChemAxon Hydrogen", "hasKeyColumn": true, "keyColumnIndex": 0, "headerRowIndex": 0}